Registered study verification

Trial Finder

A step-by-step checklist for locating and verifying registered human studies of ibogaine, noribogaine, or closely related derivatives. A study listing is not an invitation to treatment, and a careful search begins with the record—not a promotional claim.

Research workspace illustrating careful review of ibogaine clinical-trial enrollment records

01 / Start with registries

Search the record, not the pitch

Use a registry search before treating any website, social post, or intermediary as evidence that a study exists or is open.

Start with ClinicalTrials.gov’s public study record and search more than one term: “ibogaine,” “noribogaine,” a named derivative, and relevant condition terms. Search results can change as entries are added, corrected, completed, or withdrawn, so save the identifier and revisit the individual record rather than relying on a screenshot.

For studies outside the United States, check the WHO International Clinical Trials Registry Platform as an additional registry route. Registry records should be treated as a starting point for verification, not as a clinical recommendation or a statement that participation is appropriate for any individual.

Keep research separate from commercial care. A search for ibogaine treatment-center information may surface businesses or services, but commercial treatment claims do not establish that a registered human study is recruiting.

02 / Read recruitment precisely

Status is a current-condition field

A recruitment label describes the study record’s stated condition at a point in time. It is not a promise that a person can join, receive treatment, or meet eligibility criteria.

  1. Recruiting. The record indicates the study is seeking participants, but location-specific availability, screening, and eligibility still need confirmation.
  2. Active, not recruiting. The study may be underway, but it is not seeking additional participants according to the record.
  3. Enrolling by invitation. The study is not generally open; participation is limited to people chosen or invited under the protocol.
  4. Planned or not yet recruiting. The record may describe an intended study, but no enrollment should be assumed until the status and dates support it.
Close view of study-review materials used to compare protocol details and recruitment information
THE LISTING IS A CHECKPOINT—NOT A BOOKING.

03 / Verify date-sensitive details

Check the fields that change the meaning

Open the full record and read eligibility criteria, primary endpoints, study design, masking, sponsor, locations, and contact fields together. The FDA’s clinical research overview describes the structured role of clinical research; a protocol’s stated purpose and endpoints matter more than general language around innovation or access.

Record the “last updated” date, recruitment dates, and any date a result was first posted. If a record appears stale, if locations have changed, or if sponsor details do not align with the outreach you received, pause and verify through official sponsor channels. For a broader safety-oriented frame before comparing study claims, consult the site’s risks and regulations guidance.

04 / Separate research from sales

A record should withstand cross-checking

Signals to cross-check

  • The registry identifier appears consistently on sponsor materials.
  • The sponsor named in the record has an official site that matches the study description.
  • Location, recruitment status, and dates agree across the registry and sponsor information.
  • Any institutional review information is presented in a way that can be independently checked.
  • Study contacts are listed in the official record rather than routed only through a marketer.

Reasons to pause

  • Language suggests guaranteed access, outcomes, or a treatment purchase rather than research participation.
  • A listing is cited without its identifier, status, sponsor, or protocol fields.
  • Urgency, deposits, travel packages, or commercial sales are presented as conditions of “enrollment.”
  • The claimed study does not match the registry record’s intervention, recruitment, or contact details.
  • An operator blurs the distinction between a clinical trial and a paid service.

Research ethics review is a distinct oversight function. In the United States, the Common Rule framework addresses protections for human subjects; an IRB reference should be assessed as part of a broader verification process, not as a substitute for reading the registry record. Claims involving access elsewhere may also be entangled with legal and regulatory differences; ibogaine legality context is separate from proof that a given study is registered and recruiting.

05 / Practical questions

Before you treat a result as real

Use the checklist as a repeatable way to slow down. It does not replace professional medical or legal advice.

Does “recruiting” mean I can sign up?

No. It means the study record states that recruitment is underway. Eligibility criteria, site capacity, consent, screening, and study-specific decisions remain separate. A pre-screen checklist can help organize questions without treating a registry result as an enrollment offer.

What should I compare beyond the registry page?

Compare the registry identifier, sponsor name, protocol summary, locations, contact details, and dates against the sponsor’s official materials. Be particularly careful where treatment marketing is mixed with research language, including claims connected to European ibogaine treatment options or regional service directories.

Why inspect eligibility and endpoints first?

Eligibility criteria describe who the protocol is designed to study, while primary endpoints show what the investigators intend to measure. Those details help distinguish a specific research question from broad claims about treatment. The background on clinical-trial structure is useful context, but the individual record remains the document to check.

How should location claims be handled?

Check each listed site in the official record and recheck the date fields before acting on a location claim. A local search result, such as a page about Seattle-area ibogaine services, does not confirm that an identified study is operating there.

What belongs outside the trial decision?

Supplement discussions, plant-source narratives, and service information should not be used to infer trial eligibility or safety. For example, material about magnesium and ibogaine or ibogaine in Gabon is not a substitute for the registered protocol, sponsor verification, or informed-consent process.

Keep the process grounded

Verify first. Decide later.

Return to Kestara guidance